Dr. Xiaolong (Tom) Zhang joined WuXi AppTec in early 2020 as the Senior Director and U.S. head of Large Molecule Bioanalysis. He oversees operations and provides scientific and compliance supports to large molecule services including TK/PK, immunogenicity, biomarkers, PD, and cell assays. His team supports hundreds of studies covering a
variety of drug modalities (e.g., fusion protein, antibody, bispecific, gene, and CAR-T therapeutics) from early discovery to late clinical phases and provides scientific and regulatory support for a wide range of biologics.
Dr. Zhang has over 10 years of experience in CROs, academia and pharmaceutical companies. He holds Ph.D. in Biomedical Engineering from Pennsylvania State University where he also serves on the Industrial and Professional Advisory Council. He has published over 20 manuscripts in refereed journals, as well as several book chapters, invited review articles, and patents.